DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for thyroid disease — screening already-approved drugs against its 38-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleThyroid disease maps to a 38-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for thyroid disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
argonaute RISC catalytic component 2 (AGO2) — AGO2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet iphdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4Z4D · 1.6 Å · ligand PHENOL (IPH). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Endocrinology · 2017 · 25 citations · open access
Genetics of Thyroid-Stimulating Hormone Receptor—Relevance for Autoimmune Thyroid Disease
AbstractProduction of thyroid-stimulating hormone receptor (TSHR) antibodies represents the hallmark of Graves' disease (GD) pathogenesis. Thus, for more than two decades the TSHR gene has been at the center of studies intended to elucidate its contribution to disease pathology. The advent of genome-wide association technology allowed to establish a strong association of the TSHR gene with GD. Subsequent fine-mapping studies narrowed the disease-susceptibility region to a 40 kb sequence in intron 1, where at least five GD-associated SNPs in tight linkage disequilibrium were identified. The current challenge is to understand the functional mechanisms by which these polymorphisms modify physiological processes and trigger disease. The aim of this review is to summarize the current knowledge on the role of the TSHR gene in GD pathogenesis, which has been gained through linkage and association studies, as well as to discuss the emerging mechanisms underlying biological implications of TSHR variants in the development of GD.
Journal of Drug Delivery Science and Technology · 2023 · 6 citations · open access
Drug delivery systems for thyroid disease treatment: A mini review on current therapies and alternative approaches
AbstractThyroid hormones play an important role in many metabolic processes in the human body. However, these processes can often be disrupted by an over or underactivity of the thyroid gland which, if undiagnosed or untreated, can result in serious illness. Currently, therapeutic management of an underactive thyroid gland (hypothyroidism) is typically achieved via replacement therapy with levothyroxine (LEVO), a synthetic form of thyroxine. Conversely, anti-thyroid drugs (ATDs), radioactive iodine or thyroidectomy are established approaches in treating hyperthyroidism. With respect to the route of the administration, drugs to treat hypo and hyperthyroidism can typically be administered through oral (PO), intravenous (IV), and rectal (PR) routes. Despite the fact that thyroid disorders have been successfully treated for many years, several problems still exist in the conventional treatment approach. Due to issues such as poor patient compliance and concordance, poor gastrointestinal (GI) absorption when taken incorrectly, and interactions with food and other medications, the administration of these drugs often results in sub-optimal dosing with accompanying serious illness if not corrected. Other forms of drug delivery are currently being studied to overcome the dosing complications that frequently occur with LEVO and ATDs with a view to increasing both patient compliance and bioavailability of the drugs in question. This review will examine why there remains a need for novel approaches and discuss studies that have been carried out with regards to this.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
